Five Prime Therapeutics (FPRX) Misses Q3 EPS by 21c

November 4, 2016 8:12 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.72), $0.21 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $7.5 million.

Five Prime continues to expect full-year 2016 net cash used in operating activities to be less than $120 million, comprising less than $90 million used in operations and less than $30 million used for tax payments. The company estimates ending 2016 with more than $400 million in cash, cash equivalents and marketable securities.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment